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Available online 17 December 2015AbstractAim: The number of examined lymph nodes (NLN) was associated with survival of stages II and III colorectal cancer (CRC) patients.
Guidelines recommend examining at least 12 lymph nodes. This study investigated the influence of surgical specimen length on lymph
node harvest and compliance with international guidelines.
Materials and methods: This population-based study included 4,724 cases of surgically treated CRC that were diagnosed from 2002 to
2008. Multivariate analyses were performed for the main study variables (age, gender, diagnosis at screening or in symptomatic patients,
cancer site, staging, grading, number of positive nodes, neo-adjuvant treatment for rectal cancer, hospital were surgery was performed).
Fractional polynomial models investigated the relationship between continuous variables and outcomes.
Results: The NLN increased over time reaching 12 NLN in 64% of cases at the end of the study period. More NLN were associated with
young age, right colon cancer, pT3eT4 disease, stages II and III and high grade. Fewer NLN were associated with short surgical specimen
length and neo-adjuvant treatment in rectal cancer patients. Use of laparoscopy increased sharply over time.
Conclusions: NLN increased over time in accordance with international guidelines. Surgical specimen length correlated with NLN which
may determine therapeutic choices, particularly in stage II colon cancer. When harvested lymph nodes are under 10 in number and all are
negative, chemotherapy is always recommended. As specimen lengths <20 cm were associated with a high risk of inadequate NLN counts,
patients are at risk of over-treatment.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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2e6Introduction
In non-metastatic colorectal cancer (CRC), one of the
main prognostic factor is the number of examined
lymph nodes (NLN)1 which, whether positive or negative,
correlated with survival1 and indeed, since the 1990s,
guidelines have recommended a cut-off of 12 harvestedthor. Department of Surgical and Biomedical Sci-
ogy Section, University of Perugia and Perugia Gen-
Menghini, 1, San Sisto, 06156 Perugia, Italy. Tel.:
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).lymph nodes. More accurate identification of positive
cases (i.e. stage migration) was linked to more appropriate
patient selection for chemotherapy (i.e. real survival
benefit) and increased stage-specific survival.1,7 Even
though more lymph nodes were examined over the years,
population studies did not show a rise in the rate of node
positive cases,8 probably because organized screening pro-
grams contributed to diagnosis at early-stage. Moreover,
lymph node yield in CRC patients is influenced by, for
example, age, cancer site, disease stage, type of surgery,
expertise of surgeon and pathologist, pathological features
and surgical resection length.1,7,9e11ess article under the CC BY-NC-ND license (http://creativecommons.org/
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surgery (laparotomy vs laparoscopy), surgical specimen
length, number of examined lymph nodes (NLN) and
compliance with the 12 node cut-off over time to deter-
mine whether a longer specimen was associated with a
greater lymph node harvest and better disease staging.
Our population-based study was conducted in Umbria, an
Italian region with a population of about 900,000, with
24% aged 65 years or more in 2012, ranking it among
the oldest in the world. CRC is still a major health problem
with 2008e2010 standardized (European population) inci-
dence rates of 73.5 per 100,000 inhabitants per year in
males and 41.8 in females despite an organized screening
program using the fecal immunochemical test (FIT) which
was started in 2006. According to the Umbria Regional
cancer registry, an average of 845 new CRC cases were
diagnosed per year from 2002 to 2008, the period we ana-
lysed in the present study.
Materials and methods
Retrieved CRC cases from the regional cancer registry
had been registered according to international standards
for cancer registries. Data were of high quality as, for
example, no “cause of death certification only” (DCO),
which is an indicator of incomplete cancer registry data,
was present in our dataset even though many cases were
very old. Since cancer registries do not record clinical de-
tails of diagnosis, staging and treatment, details of diag-
nosis were accessed in the regional database belonging to
all seven regional pathology units. Full data on staging
and treatment were retrospectively obtained from Regional
Health Service hospital archives in all medical and radia-
tion oncology, surgery and gastroenterology centers.12
Quality control of medical archives was satisfactory as
few data were missing.
During the study period, patients received surgery in 20
centres, with over 70% being operated in the four main
regional hospitals of Umbria. Surgical specimens were
examined in seven regional pathology laboratories which
did not follow any standardized regional protocol for lymph
node examination. Lymph nodes were usually examined by
haematoxylin and eosin staining and at least 3 slices were
made.
A trained pathologist (SL) reviewed and coded staging
information. Personal data was strictly confidential and
was not released outside the cancer registry. Anonymiza-
tion techniques were used for data management within
the registry. No further ethical approval was sought.
Of 5,885 first primary CRCs, 4,724 cases underwent sur-
gery in Umbria and were included in the analysis. Exclu-
sion criteria were no surgery (708 cases); endoscopic
surgery only (196 cases); unknown treatment (4 cases);
palliative surgery (e.g. colostomy only) (151 cases); treat-
ment outside of Umbria (102 patients). Throughout the
study period lymph node resection was not performed inabout 20% of all 5,885 registered cases (Cuzick’s test
p ¼ 0.5), 1.8% of whom (mostly T1NxM0) underwent sur-
gery (trend p ¼ 0.4).
From the total sample of 4,724 cases, lymph nodes
were examined in 4,634 (98.1%) and data on both NLN
and surgical specimen length were available for 4,481
(94.9%).
Study variables included age and gender, diagnosis at
screening or at testing because of symptoms, neo-
adjuvant treatment for rectal cancers, TNM stage, grading,
number of positive nodes, hospital where surgery was per-
formed and its pathology unit, cancer site and sub-site
which were coded according to ICDO3T classification.13
Table 1 reports the few missing data for study variables.
Cancer site was re-coded in right colon (C18.0eC18.5),
left colon (C18.6eC18.7, C19), and rectum (C20).Statistical analysisUnadjusted regression models were fitted to investigate
the influence of date of diagnosis on study variables.
Linear regression analysed surgical specimen length.
Negative binomial regression analysed the NLN. Since
the likelihood ratio test for over-dispersion was significant
(p < 0.001), negative binomial regression, rather than the
Poisson model, was chosen to explore the influence of
study variables on the NLN. Surgical specimen length
was first included in the models by variable quintiles.
The shape of the relationship between surgical specimen
length and lymph nodes was further explored using frac-
tional polynomials, adjusted for the other significant
independent variables. Fractional polynomials are study
variable transformations based on selected powers as
proposed by Royston and Altman.14 Nested models corre-
sponding to the null model, the linear model and the best
fitting first- and second-degree powers were compared,
using the partial likelihood ratio test to perform linearity
and non-linearity significance tests.
A logit model investigated the influence of study vari-
ables on compliance with the recommended 12 lymph
node cut-off (model not shown). Statistical analyses were
performed using Stata software (version 13).
Results
Mean age at diagnosis was 70.8 in males and 71.7 years
in females. Nearly 75% of all cases were elderly (65
years). Over 70% of cases had pT3eT4 disease at diag-
nosis, which dropped from 74% in 2002 to 66% in 2008,
two years after the screening program had started. Stage
III or IV at diagnosis accounted for 45% of cases. Table 1
reports the distribution of study variables.
Neo-adjuvant treatment was administered in 155 cases
(3.3% of all study cases; 17% of rectal cancers).
No lymph node was examined or retrieved during sur-
gery in 87 cases and data on examined lymph nodes was
Table 1
Distribution of cases according to selected study variables.
Variables n. % P
Total cases 4724 100
Gender Males 2666 56.4
Females 2057 43.6
Age class <50 178 3.8
50e64 1079 22.9
65e74 1571 33.3
75e84 1537 32.5
85þ 358 7.6
Laterality Right colon 1715 36.3 <0.001
Left colon 1930 40.9
Rectum 1076 22.8
X 2 0.04
Grading 1 821 17.4 0.001
2 2644 56.0
3 1173 24.8
X 85 1.8
pT 0a 28 0.6 0.002
1 548 11.6
2 777 16.5
3 2947 62.4
4 397 8.4
X 26 0.6
Stage 0a 27 0.6 0.05
I 1069 22.6
II 1441 30.5
III 1256 26.6
IV 861 18.2
X 32 0.7
T1NxM0 37 0.8
Screening NSD 4273 90.5 0.001
SD 450 9.5
Abbreviations: SD, screening detected; NSD, non-screening detected.
a After neo-adjuvant chemo-radiotherapy.
Table 2
Negative binomial regression model for the number of examined lymph
nodes.a
Variables n. of examined nodes
RR L U P
Year 1.05 1.03 1.08 <0.001
Age
<50 Ref.
50e64 0.83 0.77 0.90 <0.001
65e74 0.77 0.73 0.82 <0.001
75e84 0.74 0.68 0.80 <0.001
85 0.63 0.57 0.70 <0.001
Surgeryb
Open Ref.
Laparoscopy 0.97 0.91 1.02 0.25
Laterality
Right colon Ref.
Left colon 0.86 0.82 0.91 <0.001
Rectum 0.93 0.90 0.96 <0.001
Rectum NTc 0.76 0.72 0.80 <0.001
Specimensd
Qt1 <160 Ref.
Qt2 160e199 1.20 1.16 1.25 <0.001
Qt3 200e259 1.24 1.15 1.34 <0.001
Qt4 260e349 1.32 1.19 1.46 <0.001
Qt5 350þ 1.41 1.30 1.53 <0.001
pT
1 0.77 0.67 0.88 <0.001
2 0.94 0.88 1.01 0.12
3 Ref.
4 1.02 0.99 1.05 0.14
X 0.52 0.31 0.87 0.01
Stage
I 0.90 0.84 0.98 0.01
II 1.01 0.98 1.04 0.4
III Ref.
IV 0.92 0.83 1.00 0.06
X 0.10 0.04 0.26 <0.001
Grade
1 Ref.
2 1.07 1.00 1.14 0.05
3 1.07 1.01 1.14 0.02
X 1.09 0.85 1.39 0.5
Abbreviations: CI, confidence interval; RR, relative risk; L, lower bound;
U, upper bound; OR, odds ratio.
a Also adjusted for hospital of surgical treatment [T1NXM0 and ypT0
excluded].
b Laparoscopy was forced in the model even if not significant.
c Rectum treated with neo-adjuvant therapy.
d Length of surgical specimens (mm).
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per intervention was 12, increasing linearly from 10 in
2002 to 13 in 2008 (p < 0.001) while cases with 12 exam-
ined lymph nodes increased from 43% to 64% (p < 0.001).
The unadjusted odds ratio (OR) of compliance with the rec-
ommended 12 NLN for year of diagnosis was 1.16 (95%
CI from 1.13 to 1.19). Throughout the study an average of
about 40% lymph nodes were positive but node positivity
decreased significantly over time (p ¼ 0.001, unadjusted
OR 0.94, 95% CI from 0.91 to 0.96). Table 2 reports inde-
pendent predictors of NLN according to the negative bino-
mial regression model. More NLN were associated with
young age, right colon cancer, pT3eT4 disease, stages II
and III and higher grading. Fewer NLN and poorer compli-
ance with the recommended 12 NLN cut-off were associ-
ated with neo-adjuvant treatment in rectal cancer patients
and short surgical specimen length.
Information about surgical specimen length was missing
for 161 cases. Median surgical specimen length measured
after formalin fixation was 24 cm shortening from 25 cm
in 2002 to 22 cm in 2008 (p < 0.001). The test for non-
linearity was non-significant (p ¼ 0.2). A total of 1,021 pa-
tients (21.6%) underwent laparoscopy, increasing from 4%in 2002 to nearly 40% in 2008 (p < 0.001). Median surgical
specimen length was 25 cm with open surgery and 20 cm
with laparoscopy. Laparoscopy was preferred for short re-
sections (<21 cm in 70% of operations) and open surgery
for total colectomies (>35 cm in 90% of operations).
In a regression model longer surgical specimen length
was associated with male gender, younger age, higher path-
ological tumour stage (pT), laparotomy, non-screening de-
tected tumours and right-sided tumours (Table 3).
Surgical specimens were on average about 2 cm longer in
males than in females and 2.5 cm shorter in the elderly
Table 4
Median number of examined lymph nodes and proportion of cases with
12, 7, and 0 examined lymph nodes by length of surgical specimen
class.a
Specimen length (mm) n. Median NLN % of cases with
NLN
12 7 0
29e99 149 7 19.5 54.4 9.4
100e199 1016 11 47.0 77.2 2.4
200e299 1383 13 58.7 86.3 0.9
300e399 666 13 63.7 87.8 1.2
400e499 266 13 60.5 87.6 0.4
500e599 101 13 62.4 85.1 1.0
600þ 153 14 64.7 90.2 0.7
Abbreviations: NLN, number of examined lymph nodes.
a Stage IV cases were excluded.
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associated with a 2.8 cm shorter surgical specimen than
open surgery. When laparoscopy and diagnosis at screening
were included in the model, year of diagnosis was not sig-
nificant. In the negative binomial model surgical specimen
length was a significant predictor of NLN (Table 2). When
length was 10e19 cm under 50% of cases had 12 NLN.
Length <16 cm was associated with few NLN (median
10) so a low percentage of cases (about 38%) had 12
NLN. When length was <10 cm, 19.5% of cases had
12 NLN (Table 4). There was a high risk of having <7
NLN and a nearly 10% probability of no lymph node
removal. Figure 1 illustrates the relationship between surgi-
cal specimens and NLN.
Results were adjusted for hospital where surgery was
performed. The hospital pathology laboratory did not
impact on the other study variables when it was included
in the model with the hospital. Therefore, the pathology
laboratory was not retained in the final model.
Discussion
As expected, given the guideline recommendations,
NLN increased over time in the present study, reaching a
median of 13 nodes in 2008, when 64% of cases had at least
12 examined lymph nodes, concurring with other studies.15
As reported, a better focus on guidelines and communica-
tion between surgeons and pathologists16,17 was the main
determinant of this rise in NLN which was achieved in Um-
bria, Italy without any incentive, unlike what was reported
in other countries.18 In our study a rise in NLN was associ-
ated with a drop in node positive patients, probably becauseTable 3
Regression model for the length of surgical specimens (cm).a
Variables B L U
Gender (p < 0.0001) Female Ref.
Male 2.1 1.2 3.0
Age (p ¼ 0.004) <50 1.1 3.6 1.5
50e64 Ref.
65e74 0.4 1.6 8.0
75e84 1.5 2.8 0.3
85 3.4 5.3 1.5
Laterality (p < 0.0001) Right colon Ref.
Left colon 3.3 4.3 2.2
Rectum 4.3 5.5 3.1
pT (p < 0.0001) 0b 1.2 7.0 4.7
1 3.4 4.9 1.9
2 2.1 3.4 8.6
3 Ref.
4 3.5 1.8 5.2
Surgery (p < 0.0001) Laparoscopy 2.8 4.0 1.6
Open Ref.
Screening (p ¼ 0.01) SD 2.1 3.8 0.5
NSD Ref.
Abbreviations: SD, screening detected; NSD, non-screening detected; CI,
Confidence Interval; L, lower bound; U, upper bound; B, beta coefficient.
a Also adjusted for hospital of surgery.
b After neo-adjuvant chemio-radiotherapy.more early stage cancers were diagnosed through the orga-
nized screening program.
Despite this progress, many patients were still not
receiving the optimal standard of care even at the end of
the study period. Factors impacting upon a harvest of
<12 NLN included neo-adjuvant treatment in 17% rectal
cancer patients which significantly reduced the NLN.19
Thus the median NLN was somewhat lower than for colon
cancer sites but still similar to SEER reports in the same
period.15 Furthermore, <12 NLN was linked to older age.
One might speculate that older patients, many with co-
morbidities, are less suitable candidates for extensive sur-
gery and that their dampened immunological reaction to
cancer and inflammation might not make lymph nodes
visible to the surgeon, who will not then remove them.20
Early-stage, low grade and left-sided tumours were also
associated with <12 NLN.
On the contrary, in the present study the highest number
of NLN and the most cases with at least 12 NLN were
observed in patients with advanced stage disease and the
right colon as disease site even after adjustment for stage
and specimen length. Advanced stage disease is associatedFigure 1. Relationship between surgical specimen length and number of
examined lymph nodes.
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des visible for removal22,23 while right colon tumours are
associated with micro-satellite instability18,23 and other var-
iations in tumour biology, which might account for the
greater lymph node counts.
The present study confirmed surgical specimen length
was an independent predictor of NLN9e11,20,21,24,25 as, in
all tumour localizations, longer specimens have signifi-
cantly more lymph nodes in their surrounding tissues.
Very short surgical specimens (<10 cm) correlated with a
low NLN, as only 19% of cases had 12 or more, and
46% of cases had under 7 NLN. When surgical specimens
were 10e19 cm in length compliance with the 12 NLN
recommendation was still <50%. Longer surgical speci-
mens were found in males, younger patients, non-
screening detected tumours, tumours with a high patholog-
ical stage and localized in the right colon. On the other
hand, short surgical specimens were associated with lapa-
roscopy, which was increasingly used due to early stage
diagnosis. Laparoscopy offers several advantages over
open surgery in the immediate post-operative period.
When performed by an expert surgeon it is as safe and as
effective as open surgery.6 Compared with open surgery,
laparoscopy was not associated with significantly different
lymph node harvests26e28 but was associated with spec-
imen length which, in turn, impacted on NLN. Thus, the
lower NLN which was associated with laparoscopy in the
present study did not reflect a lower lymph node yield for
specimens of similar length, but surgeon preference for
an open surgery when large resections were required (e.g.
total colectomies).
NLN correlated with overall survival in stages II and III
colon cancer1 and may determine therapeutic choices. In
node positive patients, adjuvant chemotherapy is standard
treatment. A large NLN harvest may counteract the meta-
static spread through the lymphatic drainage system. In
node negative patients a large NLN harvest will define
those for whom surgery alone should be curative while
poor node harvesting might mask stage III disease, thus
denying them the benefit of adjuvant chemotherapy and
therefore lowering survival rates.29 In fact, chemotherapy
is always recommended for patients with under 10 har-
vested negative lymph nodes.6 In the present study speci-
mens <20 cm were associated with a high risk of
inadequate NLN and, among node negative patients, 47%
of cases had less than 10 examined nodes vs 30% when
specimens where 20 cm. Furthermore, we could hypoth-
esize a certain degree of over-treatment for those true node
negative patients which, due to less than 10 NLN, received
adjuvant chemotherapy.
Could a more accurate node evaluation reduce the
number of patients who are referred to chemotherapy by
better identification of positive nodes? The relevance of
micrometastases in stage II CRC survival has been appre-
ciated for many years.29,30 Sentinel node mapping mayidentify more nodal metastases than standard pathological
techniques, and meticulous detection of occult microme-
tastatic disease may upstage the disease, and impact posi-
tively on survival. However, due to the relatively high rate
of false negative cases, sentinel node biopsy is now sug-
gested not as an alternative to standard lymphadenectomy,
but as an additional approach that improves staging.31
The main limitations of the present study are common to
cancer registry-based analyses: retrospective nature, delay
in data reporting and lack of uniformity in diagnostic and
treatment protocols. For example, in the present study, there
was no shared protocol for node examination, even though
all centres made at least 3 slices. On the other hand, our
large unselected patient cohort constituted the main study
advantage as it provided data on differences in routine clin-
ical practice which could be extrapolated to the general
population.
In conclusion, present findings indicate a 6-year trend
towards more conservative surgical approaches like lapa-
roscopy for CRC, a larger lymph node harvest and better
compliance with 12 NLN for all sites, particularly the
right colon and rectum when not treated with neo-
adjuvant chemo-radiotherapy. Surgical specimen length
emerged as a major determinant of NLN and compliance
with international guidelines. Since specimens <20 cm
were associated with a low NLN, they should be avoided
so as to reduce the risk of over-treatment as adjuvant
chemotherapy is recommended for node negative patients
with under 10 NLN. Otherwise, strategies to increase
NLN should be used when short resections are
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